SPX3,647.29-7.75 -0.21%
DIA291.30-1.42 -0.49%
IXIC10,829.50+26.58 0.25%

Altimmune Shares Fall Despite Company's Report of Pemvidutide Phase 1b Study Successfully Meeting All Endpoints

Altimmune Shares Fall Despite Company's Report of Pemvidutide Phase 1b Study Successfully Meeting All Endpoints

MT Newswires · 09/14/2022 07:18

Please log in to view news